TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Evaluation of the benefit of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Validity of study conclusion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MRI-PDFF threshold for predicting metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of gastric insufflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Risk of distant recurrence
Endpoint domain: Mortality/survival
Primary endpoint: decreased risk of stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: increased risk of myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: increased risk of cardiac event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall cognitive functioning posttreatment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Hemorrhage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Vancouver scar scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child HAZ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in moderate-intensity physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in physical activity goal setting
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: improvement in enjoyment of physical activity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Five-time sit-to-stand test time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical-limb knee extension moments during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin-stimulated R(d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in the MADRS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BTCQ scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Finger dexterity test improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prolonging pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chorioamnionitis
Endpoint domain: Adverse events/effects
Primary endpoint: composite neonatal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: X-ray changes in skeletal fluorosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall success rate of ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite AT intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent clearance of 10‐monohydroxy metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum postdose [Na+] measurement ≤125 mEq/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: >10 mEq/L decrease in [Na+] from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hyponatremia-related TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Antinociceptive effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FADI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale for pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity associated with DVT
Endpoint domain: Adverse events/effects
Primary endpoint: Ankle dorsiflexion at final follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Superficial and deep infections
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with fewer than 400 copies of HIV RNA per milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with fewer than 50 copies of HIV RNA per milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to loss of virologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak fluorescence intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Admission Hb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peak Hb levels during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total length of stay
Endpoint domain: Resource use
Primary endpoint: Mean number of ischemic episodes per 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean duration of ischemia for 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Angina frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: subjective pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morphine use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diaphragm contractile efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: weekly healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV-1/FVC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: onset of bronchodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall intubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in health knowledge scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: overall prostate cancer risk
Endpoint domain: Mortality/survival
Primary endpoint: depression scale percentage change scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasminogen activator inhibitor type 1 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak activation during WBE compared to RE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall OIIRR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure (IOP) measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Thermal injury to vital pulp
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of seal of pulp exposure hole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Agreement between EBUS‐TBNA and mediastinoscopy for mediastinal staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity for mediastinal lymph node staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications from EBUS‐TBNA and mediastinoscopy
Endpoint domain: Adverse events/effects
Primary endpoint: decrease in overall visual analogue scale pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: return of bowel movement after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: discharge time after surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Phase advances of the melatonin rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Response duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Exhaled nitric oxide level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Levels of interleukin-1α, interleukin-1β, and interleukin-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ejection duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Impairment in multiple life domains
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Increase in inter-jaw angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in inclination of the posterior occlusal plane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior and lower adaptation of the mandible
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of analgesia-related adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: relative effectiveness of genotype‐guided warfarin initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to determine exposure to electric and magnetic fields
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year event free survival
Endpoint domain: Mortality/survival
Primary endpoint: Coronary artery patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: performance-based mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of falls
Endpoint domain: Adverse events/effects
Primary endpoint: HIV-1 viral load <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PLM index (PLMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PLM during sleep with arousal index (PLMSAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (no retching/vomiting and no need for rescue anti-emetic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: femoral adipose tissue meal FA storage rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fasting LPL activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fed LPL activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to complete recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binding antibodies for Env
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4(+) T cell response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD8(+) T cell response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average time to recover 50% of prechallenge skin temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average time to recover 70% of prechallenge skin temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digital blood flow measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stenosis of the antrostomy site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating IGFBP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: MD-IGF-I levels in Ex-leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: MD-IGF-I levels in Rest-leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Energy intake at lunch per kilogram of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participants' hunger
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Satiety and fullness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Sensitivity of PCR assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of PCR assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of indeterminate results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Processing time for cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work-hours necessary to process results
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean measured reflux of volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% or greater decrease in baseline Hamilton Depression Rating Scale (HAM-D) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Improvement (CGI) scale score change of 'much' or 'very much' improved
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 50% or greater decrease in baseline Montgomery-Asberg Depression Rating Scale (MADRS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4+ T-cell activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD8+ T-cell activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-priming antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Opsonophagocytic activity titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Likelihood of abstaining from drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in somatosensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: virological suppression with VL <200 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: virological suppression with VL <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: superiority of trigone-including injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of VUR
Endpoint domain: Adverse events/effects
Primary endpoint: PF TNF-alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication adherence scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation in the ventral tegmental area (VTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Individual knee pain scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean predialysis body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of peak stress RWMAs per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intradialytic systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive rate of anti-HBs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean titer (GMT) of anti-HBs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective rate of anti-HBs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: therapeutic activity in treating erythema, papules, edema, and itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change scores for hyperactivity/impulsivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change scores for oppositionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change scores for social skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of serious or nonserious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory test abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arrhythmia appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: premature ventricular contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma K concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrence of atrial tachyarrhythmias (ATa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major Adverse Limb Event-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Composite of death from cardiac causes, myocardial infarction, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Increased pulse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Augmentation of anxiety scale parameters
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in enthesitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in physical function/HRQOL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reported anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IL-21 as a predictor of adverse remodelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 120-min glucose area under the curve of OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rise of low-density lipoprotein cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: minimum hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Development of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Serum TLC rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 h Energy Expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Desire to smoke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: better general health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: less intrusive thoughts
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: stronger preferences in decision making
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Inhibition of thromboxane B2 (TXB2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inhibition of prostaglandin E2 (PGE2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects and postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of red blood cells, white blood cells, platelets, lactate dehydrogenase, blood urea nitrogen, and alanine aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: microvascular blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: vessel delineation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detection of collaterals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk flexion ROM improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprocedural pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-scored GRS score change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: confidence performing a VH
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: physical self-esteem
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: family self-esteem
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FEV(1) variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dlco variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total score of NRS-R
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful primary placement of catheters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repositioning of catheters after successful placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BADS' profile score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative functional lung volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: reduction in stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lower maximum blood glucose excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes